Litigation Details for United States v. Indivior Inc. (W.D. Va. 2019)

United States v. Indivior Inc. (W.D. Va. 2019)

Docket		Date Filed	2019-04-09
Court	District Court, W.D. Virginia	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	8,475,832; 8,921,387; 8,975,270; 9,180,197; 9,186,413; 9,272,044
Link to Docket	External link to docket

Details for United States v. Indivior Inc. (W.D. Va. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-09	115	Superseding Indictment	atentTitle um ber (1) 8,475,832 Sublingualandbuccalfilm compositions …,4718643 b. Patents: Patent P … TheDrugPriceCompetition andPatentTerm RestorationAct(ill-latch-W axman Act'&	External link to document

United States v. Indivior Inc. | 1:19-cr-00016-JPJ-PMS-2: Litigation Summary and Analysis

Last updated: August 15, 2026

United States v. Indivior Inc., No. 1:19-cr-00016-JPJ-PMS-2, was a federal criminal and civil enforcement matter concerning Indivior's marketing of Suboxone Film, a buprenorphine and naloxone product used to treat opioid dependence. The government alleged that Indivior misled health-care providers, state Medicaid programs, and the FDA about the product's safety and promoted it through an improper patient-referral program.

The matter was resolved through a coordinated criminal and civil settlement announced in October 2019. Indivior Solutions Inc., an Indivior subsidiary, pleaded guilty to felony misbranding. Indivior Inc. entered into a deferred prosecution agreement and agreed to substantial monetary payments. The total resolution was approximately $600 million, comprising criminal penalties, forfeiture, and civil payments.[1]

What was United States v. Indivior Inc. about?

The case concerned alleged fraud and misbranding in the promotion of Suboxone Film. Suboxone Film contains buprenorphine and naloxone and is administered orally through a sublingual or buccal film.

The government alleged that Indivior:

• Promoted Suboxone Film as safer than Suboxone tablets despite allegedly lacking adequate support for that claim.
• Targeted physicians who prescribed opioid-dependence treatments.
• Misled state Medicaid programs and commercial insurers about the product's safety profile.
• Used a program called "Here to Help" to influence patients and physicians and steer prescriptions toward Suboxone Film.
• Submitted false or misleading information to the FDA concerning the relative safety of the film and tablet formulations.
• Sought to delay or limit competition from generic Suboxone tablets and other buprenorphine products.

The indictment charged Indivior Inc. with a broad series of offenses, including conspiracy, health-care fraud, wire fraud, mail fraud, false statements, and violations involving the introduction of a misbranded drug.[2]

Which companies and entities were defendants?

Indivior Inc.

Indivior Inc. was the principal corporate defendant identified in the criminal case. It entered into a deferred prosecution agreement rather than resolving the matter through a conventional guilty plea on all indictment counts.

Indivior Solutions Inc.

Indivior Solutions Inc. was a related corporate entity. It pleaded guilty to a felony charge involving the misbranding of Suboxone Film.[1]

Reckitt Benckiser Group

The alleged conduct occurred while the Suboxone business was part of Reckitt Benckiser Group. Reckitt separated Indivior as an independent public company in 2014. The government’s enforcement actions therefore involved conduct predating and following the corporate separation.

Reckitt separately agreed in 2019 to pay approximately $500 million to resolve related federal claims concerning the marketing of Suboxone.[3]

What charges did the government bring?

The 2019 indictment contained 28 counts. The charges included the following categories:

Charge category	Government theory
Conspiracy	Agreement to market Suboxone Film through misleading representations
Health-care fraud	Alleged efforts to induce prescriptions and payments through false statements
Wire fraud	Electronic communications used to transmit allegedly misleading marketing information
Mail fraud	Use of interstate mail in the alleged scheme
False statements	Alleged false or misleading submissions to federal agencies
Misbranding	Promotion and distribution of Suboxone Film with allegedly misleading labeling or claims

The case was broader than a conventional FDA labeling dispute. The government connected the alleged promotional conduct to reimbursement decisions by Medicaid programs and other payors. That structure allowed prosecutors to pursue both Food, Drug, and Cosmetic Act violations and federal health-care fraud theories.

How did the government describe Indivior’s Suboxone marketing?

The government focused on three related allegations.

Safety comparisons between Film and Tablet

Prosecutors alleged that Indivior promoted Suboxone Film as less susceptible to pediatric exposure and accidental ingestion than Suboxone tablets. The government contended that Indivior lacked adequate clinical support for the superiority claims and did not fairly communicate the available safety information.

The "Here to Help" program

The government alleged that Indivior operated the "Here to Help" program as a patient-assistance and referral mechanism. According to the indictment, the program helped direct patients to physicians who were more likely to prescribe Suboxone Film.

The prosecution treated the program as part of the commercial strategy rather than as an independent patient-support activity. The allegations raised risks under federal health-care fraud and anti-kickback principles, even though the principal criminal resolution was framed around misbranding and related conduct.

Medicaid and insurer reimbursement

The government alleged that Indivior made representations to state Medicaid programs and other payors to obtain coverage and reimbursement for Suboxone Film. The alleged misrepresentations concerned safety, abuse potential, and the comparative merits of film and tablet formulations.

What was the settlement amount in the Indivior criminal case?

The overall resolution was approximately $600 million. Public descriptions of the settlement allocated the payment among criminal penalties, forfeiture, and civil claims.

Component	Approximate amount	Recipient or legal basis
Criminal penalty	$289 million	Federal criminal resolution involving Indivior Inc.
Forfeiture and related criminal payments	Approximately $108 million	Federal forfeiture resolution
Civil settlement	Approximately $203 million	Federal and state health-care claims
Total	Approximately $600 million	Combined criminal and civil resolution

The precise allocation depended on the entity and agreement involved. The $600 million figure should not be treated as a single penalty imposed on one defendant in one procedural instrument. The resolution covered multiple entities and legal theories.[1]

What was the deferred prosecution agreement?

A deferred prosecution agreement is a negotiated resolution in which the government files or maintains criminal charges but agrees to defer prosecution for a specified period. The company generally must satisfy compliance, cooperation, payment, and reporting obligations. If it complies, the government may dismiss the charges at the end of the deferral period.

For Indivior Inc., the agreement required the company to:

• Pay the agreed criminal and civil amounts.
• Cooperate with ongoing government investigations.
• Maintain a compliance program.
• Implement controls over marketing, sales, medical affairs, and reimbursement communications.
• Avoid further violations during the deferral period.

Indivior Solutions Inc.'s guilty plea created a separate criminal disposition from Indivior Inc.'s deferred prosecution arrangement.[1]

What was the litigation timeline?

Date	Event
2014	Indivior separated from Reckitt Benckiser as an independent company
April 2019	DOJ announced the indictment of Indivior Inc. in the Western District of Virginia
April 2019	The government described a 28-count indictment involving Suboxone Film marketing
October 2019	Indivior Solutions Inc. pleaded guilty to felony misbranding
October 2019	Indivior Inc. entered a deferred prosecution agreement and agreed to financial penalties
October 2019	DOJ announced an approximately $600 million combined criminal and civil resolution
2019	Reckitt separately agreed to a major federal resolution involving related Suboxone conduct

The docket designation identifies the Western District of Virginia proceeding before District Judge James P. Jones, with magistrate-judge involvement under the docket suffix "-2." The criminal matter was resolved through negotiated agreements rather than a trial verdict.

Did Indivior face a Paragraph IV patent challenge?

The criminal case was not a Paragraph IV patent case. It did not determine the validity, enforceability, or infringement of Suboxone patents.

The case did have commercial overlap with generic competition. The government alleged that Indivior's marketing strategy helped protect Suboxone Film from competing products and preserve reimbursement. That commercial context is distinct from a patent infringement action under the Hatch-Waxman Act.

A Paragraph IV certification is an FDA-related patent challenge submitted by an abbreviated new drug application applicant. The Indivior criminal docket did not adjudicate such a certification. Patent disputes concerning Suboxone products were litigated in separate federal proceedings and should not be treated as part of No. 1:19-cr-00016-JPJ-PMS-2.

What FDA regulatory issues were involved?

The FDA-related allegations concerned the accuracy and adequacy of information provided about Suboxone Film. The government alleged that Indivior made misleading statements about comparative safety and the risk of accidental pediatric exposure.

The regulatory theories included:

• Misbranding under the Federal Food, Drug, and Cosmetic Act.
• False or misleading communications to the FDA.
• Promotional claims that allegedly exceeded the supporting evidence.
• Commercial use of safety claims in physician and payor communications.

The case illustrates the overlap between FDA enforcement and False Claims Act exposure. When a drug company allegedly uses misleading labeling or promotional statements to obtain Medicaid reimbursement, the same conduct can support both regulatory and monetary claims.

What was the impact on Suboxone Film and generic competition?

The matter increased commercial and compliance risk for Suboxone Film, but it did not invalidate the product's FDA approval. Suboxone Film remained an approved treatment for opioid dependence.

The enforcement action affected competition in four ways:

1. It increased scrutiny of switching strategies from tablets to film.
2. It created potential reimbursement risk for claims influenced by allegedly misleading safety representations.
3. It increased compliance obligations for marketing and patient-support programs.
4. It gave generic manufacturers and payors evidence relevant to commercial conduct, although the criminal resolution itself did not establish patent invalidity.

Generic competition to buprenorphine products remained a separate Hatch-Waxman and market-access issue. The criminal resolution did not create an automatic generic launch date and did not remove patent protections from the Orange Book.

How strong was the government's case?

The government's case was sufficiently strong to produce a negotiated resolution involving a guilty plea by an Indivior subsidiary and a deferred prosecution agreement with Indivior Inc. The size of the payment indicates substantial litigation and regulatory exposure.

The resolution also limited the government's trial risk. A trial would have required the government to prove intent, materiality, causation, and the relationship between promotional statements and federal health-care payments across a complex period involving corporate separation and multiple products.

For Indivior, the agreement reduced the risk of a broader conviction, exclusion from federal health-care programs, and additional damages. It also avoided the operational uncertainty of a trial while imposing significant financial and compliance costs.

What patent and commercial issues remain separate from the case?

The criminal docket does not resolve:

• Whether Suboxone patents were valid or enforceable.
• Whether a generic product infringed any listed patent.
• Whether Indivior engaged in unlawful patent settlement conduct.
• Whether a particular film or tablet patent survived an inter partes review.
• Whether an ANDA applicant could launch before patent expiration.
• Whether later generic entry reduced Suboxone revenue.

Those issues require review of separate patent, antitrust, FDA, and commercial records. The criminal case is most relevant to promotional compliance, payor communications, product-switching strategies, and corporate governance.

What are the key business implications?

Revenue exposure

Suboxone was a major commercial asset during the period covered by the allegations. The enforcement action threatened revenue through fines, restitution or civil payments, payor scrutiny, reputational damage, and increased compliance costs.

Compliance exposure

Drug companies face elevated risk when patient-support programs, provider referrals, reimbursement communications, and comparative safety claims operate together. The Indivior case shows that prosecutors may treat those activities as an integrated commercial scheme.

M&A and spin-off diligence

The case also has relevance for corporate separations. Conduct occurring before a spin-off may remain relevant to successor entities, indemnification rights, escrow arrangements, and disclosure obligations. Drug-company transactions involving marketed products require diligence on promotional claims, Medicaid submissions, patient programs, FDA correspondence, and government subpoenas.

Litigation strategy

The resolution demonstrates that criminal, civil, FDA, Medicaid, and corporate-liability theories can be coordinated. A company facing a marketing investigation must assess exposure across all of those channels rather than treating the matter as a single labeling dispute.

Key Takeaways

• United States v. Indivior Inc., No. 1:19-cr-00016-JPJ-PMS-2, concerned alleged fraud and misbranding in the marketing of Suboxone Film.
• The indictment contained 28 counts involving conspiracy, health-care fraud, wire fraud, mail fraud, false statements, and misbranding.
• Indivior Solutions Inc. pleaded guilty to felony misbranding.
• Indivior Inc. entered a deferred prosecution agreement.
• The combined criminal and civil resolution was approximately $600 million.
• The case did not decide Suboxone patent validity, infringement, Orange Book status, or Paragraph IV rights.
• The principal legal risk involved misleading promotional claims, patient-referral activity, FDA communications, and Medicaid reimbursement.
• The matter remains a significant compliance precedent for branded-drug marketing and patient-support programs.

FAQs About United States v. Indivior Inc.

Was Indivior convicted after a trial?

No. The matter was resolved through negotiated agreements. Indivior Solutions Inc. entered a guilty plea, while Indivior Inc. entered a deferred prosecution agreement.

Did the case involve opioid distribution charges?

The case involved the marketing of an opioid-dependence treatment, not allegations that Indivior unlawfully distributed opioids through a controlled-substance trafficking scheme.

Did Indivior admit that Suboxone Film was unsafe?

The resolution concerned alleged misleading safety and marketing representations. It did not amount to a general finding that FDA-approved Suboxone Film was unsafe or that the product approval was invalid.

Did the settlement prohibit Indivior from selling Suboxone?

No. The settlement imposed financial and compliance obligations but did not revoke FDA approval or impose a general prohibition on selling Suboxone Film.

Is the Indivior case relevant to later pharmaceutical investigations?

Yes. The case is relevant to investigations involving comparative safety claims, Medicaid reimbursement, patient-support programs, provider steering, FDA submissions, and marketing conduct designed to shift prescriptions from one formulation to another.

References

1. U.S. Department of Justice. (2019, October 24). Indivior Inc. agrees to pay $600 million to resolve criminal and civil claims.
2. U.S. Department of Justice. (2019, April 9). Indivior Inc. indicted for fraudulently marketing Suboxone Film.
3. U.S. Department of Justice. (2019, September 11). Reckitt Benckiser Group agrees to pay $500 million to resolve potential criminal and civil liability related to Suboxone.
4. United States District Court for the Western District of Virginia. (2019). United States v. Indivior Inc., No. 1:19-cr-00016-JPJ-PMS-2. ensued